Oncology
CAR-TCR 2023 – Becky Cap

CAR-TCR 2023 – Becky Cap

In an industry growing as quickly as cell therapy, keeping up with the demands of manufacturing and treatment is a challenge for the whole industry to tackle together, including stakeholder

Oncology
CAR-TCR 2023 – Jason Noon

CAR-TCR 2023 – Jason Noon

If we learned anything at CAR-TCR it’s that CAR-T therapies are still a relatively new treatment modality and innovation is happening along many different axes.

Oncology
Greg Deener at CAR-TCR

CAR-TCR 2023 – Greg Deener

In late August, pharmaphorum traveled to Boston to cover CAR-TCR, a conference dedicated to the fast-moving cell therapy space.

Oncology
Greg Deener at CAR-TCR

CAR-TCR 2023 – Greg Deener

In late August, pharmaphorum traveled to Boston to cover CAR-TCR, a conference dedicated to the fast-moving cell therapy space.

Digital

Digital
Reuters Pharma USA Maria Whitman

Reuters Pharma USA – Maria Whitman

For decades, the pharma industry has been building commercialisation models that put field reps at the heart of the engagement equation.

Market Access

R&D
Reuters Pharma USA – Lung-I Cheng

Reuters Pharma USA – Lung-I Cheng

Cell and gene therapies continue to be hot topics in the pharma world this year, and some companies are responding to the new treatment modalities with new business units.

Oncology

Oncology
CAR-TCR 2023 – Becky Cap

CAR-TCR 2023 – Becky Cap

In an industry growing as quickly as cell therapy, keeping up with the demands of manufacturing and treatment is a challenge for the whole industry to tackle together, including stakeholder

Oncology
CAR-TCR 2023 – Jason Noon

CAR-TCR 2023 – Jason Noon

If we learned anything at CAR-TCR it’s that CAR-T therapies are still a relatively new treatment modality and innovation is happening along many different axes.

Newsletters and Deep Dive
digital magazine

Patients

R&D
Health Innovators Cytokinetics

Health Innovators – Fady Malik and Steve Heitner

In this instalment of Health Innovators, EiC Jonah Comstock sits down virtually with Fady Malik, EVP of research and development at Cytokinetics and Steve Heitner, the company’s VP of clinical rese

Digital
Reuters Pharma USA Maria Whitman

Reuters Pharma USA – Maria Whitman

For decades, the pharma industry has been building commercialisation models that put field reps at the heart of the engagement equation.

R&D

R&D
Health Innovators Jennifer Schranz

Health Innovators – Jennifer Schranz

In the rare and ultra-rare disease space, the paucity of both data and patients makes everything about research and development more complicated.

R&D
Health Innovators Cytokinetics

Health Innovators – Fady Malik and Steve Heitner

In this instalment of Health Innovators, EiC Jonah Comstock sits down virtually with Fady Malik, EVP of research and development at Cytokinetics and Steve Heitner, the company’s VP of clinical rese

R&D
Reuters Pharma USA – Lung-I Cheng

Reuters Pharma USA – Lung-I Cheng

Cell and gene therapies continue to be hot topics in the pharma world this year, and some companies are responding to the new treatment modalities with new business units.